Introduction
============

Heart failure (HF) is one of the leading causes of mortality in the world and is a final common pathway of several cardiovascular diseases such as hypertension, myocardial infarction, volume overload, and cardiomyopathies.[@b1-ARYA-10-001],[@b2-ARYA-10-001]

For the vast majority of patients, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), beta-blockers, diuretics, and digoxin are the main treatment choices.[@b3-ARYA-10-001]

Recent studies mentioned the role of oxidative stress and inflammation in the treatment of heart failure. Statins play an important role in lowering the pro-inflammatory markers in congestive heart failure (CHF) patients independent of their lipid lowering effect which triggered their use as an adjunctive therapy in CHF.[@b4-ARYA-10-001] Coenzyme Q10 (CoQ10) is a vitamin-like agent which is structurally similar to vitamin K.[@b5-ARYA-10-001] It was first isolated from beef mitochondria in 1957 and then found in other organs such as the heart, brain, and liver.[@b6-ARYA-10-001] CoQ10 is a fat soluble quinon which enhances cell membrane stabilization and mitochondrial energy production, and also has antioxidant effects.[@b7-ARYA-10-001],[@b8-ARYA-10-001] Recent studies have shown that statins have antioxidant activity, by means of activation of superoxide dismutase; moreover, some statins have been shown to reduce the endogenous CoQ10 levels through inhibition of 3-hdroxy 3-methyl glutaryl CoA reductase (HMG-CoA reductase).[@b9-ARYA-10-001]

Previous studies showed that serum CoQ10 levels are lower in CHF patients than in the normal population which shows the importance of using its supplement in Patients with CHF.[@b10-ARYA-10-001]

As mentioned above, statins and CoQ10 can be used as adjuncts in the treatment of CHF due to their anti-inflammatory and antioxidant effects, respectively. However, this matter remains a controversial issue.[@b9-ARYA-10-001],[@b11-ARYA-10-001]-[@b13-ARYA-10-001] The aim of the present study was to compare the effect of the addition of atorvastatin/CoQ10 combination to standard CHF treatment with that of the addition of atorvastatin alone on CHF outcomes.

Materials and Methods
=====================

**Trial design and participants**

This study was a single centre, double blind, randomized, placebo-controlled clinical trial with parallel design which was performed in Chamran Hospital, a tertiary referral centre in Isfahan, Iran. During a period of 7 months, May 2012 to February 2013, 62 consecutive patients who met the inclusion criteria were enrolled in the study. Eligibility criteria were documented CHF, ejection fraction (EF) of less than 40%, compensated heart failure without hospital admission during the previous 3 months, no change in type and dose of medications in the last months, and New York Heart Association Function Class (NYHA FC) 2 to 4. Patients were excluded if any of the following criteria were present: acute coronary syndrome developing in the last month; active myocarditis; active pericarditis; uncontrolled hypertension; hepatic failure (Child B, C); pulmonary or renal failure; and heart failure with KILLIP classification 3 and 4.

Written informed consents were obtained from all patients for authorized use of their medical records for research purposes. Moreover, the protocol was approved by the ethical committee of our university.

In this study, a sample size of 30 in each group was calculated using statistical formula considering α = 0.05 and β = 0.2. This study was a double blind trial. For the purpose of blindness of patients, placebo was made with the same shape and size of the actual drugs, and for the blindness of physicians the drugs were delivered to patients by one of the study investigators who did not perform the echocardiography and determination of NYHA FC grade.

**Intervention**

Patients who enrolled in the study were randomly divided into 2 groups, using Random Allocation Software the sequence generation was performed by one of the study investigators who did not play a role in the clinical assessments and drug delivery to patients.[@b14-ARYA-10-001] Patients in the first group (intervention) received 10 mg atorvastatin (Abidi, Iran) daily plus CoQ10 pearl supplement (USA, manufactured in Sobhan, Isfahan, Iran) with the dose of 100 mg twice daily for 4 months. In the other group (placebo), patients received 10 mg atorvastatin daily and the placebo of CoQ10 pearl, with the same shape and size of the drug, for 4 months. Placebo pearls were produced in the School of Pharmacology of Isfahan University of Medical Sciences. In both study groups, patients received standard CHF medication. The drugs were delivered to patients by one of the study investigators. The dose of drugs used in this study was determined according to previous studies performed in this field.[@b5-ARYA-10-001]

**Assessments and outcomes**

In all patients, baseline data including age, sex, weight, history of diabetes and myocardial infarction, previous use of beta blockers, and ACEI were collected. In the first visit, for each patient, echocardiography was performed using Vivid 7, USA device by one of the study investigators (JS) who was blinded to the patients' group. EF and cardiac index (CI) were determined. Blood samples were taken and N-terminal B-type natriuretic peptide , total cholesterol (TC), low density lipoprotein (LDL), erythrocyte sedimentation rate (ESR), and C reactive protein (CRP) levels were recorded. NYHA FC was also determined for each patient. Glomerular filtration rate (GFR) was calculated. After the study period (4 months), echocardiography was repeated by the same device and the same investigator, NYHA FC was calculated for the second time, and laboratory tests were checked again in the same laboratory in which previous tests had been performed. The primary outcome of this study was the effect of the addition of the atorvastatin and CoQ10 combination supplement to standard regiment on cardiac EF, in comparison with atorvastin and placebo. Secondary outcomes were the comparison of change in NYHA FC, CI, NT-proBNP, TC, LDL, ESR, and CRP.

**Statistical analysis**

Statistical analysis was performed using SPSS for Windows (version 16; SPSS Inc., Chicago, IL, USA). Student's t-test was used for parametric variables, chi-square test was used for nonparametric variables, and Man-Whitney test for data without normal distribution pattern. Statistical difference was considered significant if P \< 0.05.

Results
=======

During the period of the project a total number of 62 patients were enrolled in the study. Patients' enrolment, allocation, and follow up are shown in [figure 1](#f1-ARYA-10-001){ref-type="fig"}.

Demographic data in both study groups are shown and compared in [table 1](#t1-ARYA-10-001){ref-type="table"}. There was no statistically significant difference in study parameters between the groups. All patients had used ACEI and beta blocker before the study began. After 4 months, all patients were alive and came back for follow up.

Data analyses showed EF and NYHA FC changed significantly before and after the study period in the intervention group; however, these changes were not significant in the placebo group (P \< 0.01 for both parameters). Other parameter changes did not differ significantly between the study groups. Detailed data are shown in [table 2](#t2-ARYA-10-001){ref-type="table"}.

Discussion
==========

The aim of the present study was to compare the effect of the addition of the CoQ10/atorvastatin combination to standard CHF treatment with that of the addition of atorvastatin alone on CHF outcomes. Our study results showed that EF, as the primary outcome of the study, increased significantly in the intervention group in comparison with the placebo group. Among secondary outcomes, NYHA FC decreased significantly in the intervention group in comparison with the placebo group.

Langsjoen and Langsjoen have evaluated heart failure outcome by the administration of CoQ10 supplement and found an increase in EF and notable clinical improvement by decrease in NYHA FC.[@b15-ARYA-10-001] In line with this study and several other studies, including a recent meta-analysis performed by Sander et al[@b5-ARYA-10-001], Okello et al[@b9-ARYA-10-001] and Fotino et al.[@b16-ARYA-10-001] in this field we found an increase in EF and decrease in NYHA FC. The effect of CoQ10 on EF can be explained in this way that CoQ10 reduces the reactive oxygen species which rise in heart failure; on other hand, CoQ10 reduces peripheral vascular resistance and improves the heart pomp to push blood.[@b17-ARYA-10-001]-[@b20-ARYA-10-001]

In a meta-analyses performed by sander et al., they mentioned that patients who use heart failure treatment, including ACEI, may not be gain benefit by using CoQ10 for EF improvement; however, in contrast with this study we found that in patients who are using ACEI drugs, EF increased by administration of CoQ10 supplement.[@b5-ARYA-10-001]

Previous studies mentioned that CoQ10 supplement improves lipid profile. Shojaei et al., in their study, revealed that CoQ10 supplement reduces serum lipoprotein (a) level in patients using statin, but other serum lipids did not change significantly which can be due to the concomitant use of statin.[@b21-ARYA-10-001] In line with this study, our results showed that although there is reduction in TC and LDL, the difference of this change between study groups was not significant.

About the other markers, such as BNP, ESR, and CRP, although there was a decrease in their level, the difference between the 2 groups was not significant. In line with our study, the study by Okello et al. showed a decrease in pro-inflammatory markers by the administration of CoQ10 as an adjunctive treatment of heart failure.[@b9-ARYA-10-001]

Our study also had a limitation; the follow up in our study was 4 months. Furthermore, studies with longer follow up period are recommended in order to evaluate survival rate.

In conclusion, we deduce that the combination of atorvastatin and CoQ10 as an adjunctive treatment of heart failure increase EF and improve NYHA FC in comparison with single use of atorvastatin. We did not found a difference in other parameters such as ESR, CRP, LDL, TC, NT-proBNP, and CI.
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###### 

Demographic data in the study groups

                        Intervention group (n = 32)   Placebo group (n = 30)   P
  --------------------- ----------------------------- ------------------------ ------
  Age                   50.70 ± 12.5                  54.47 ± 14.6             0.27
  GFR (ml/minute)       72.29 ± 19.7                  64.20 ± 20.7             0.12
  Male                  23 (71.9%)                    22 (73.3%)               0.89
  History of diabetes   7 (21.9%)                     11 (36.7%)               0.20
  History of MI         13 (40.6%)                    14 (46.7%)               0.63

Data are presented as mean ± standard deviation and number (%); GFR: Glomerular filtration rate, MI: Myocardial infarction

###### 

Comparison of parameters between study groups before and after the study period

              Intervention group   P               Placebo group                                       P               Mean's difference   Standard error   P               
  ----------- -------------------- --------------- --------------------------------------------------- --------------- ------------------- ---------------- ------- ------- ---------------------------------------------------
  EF          18.7 ± 10.3          24.2 ± 14.5     0.003[\*](#tfn2-ARYA-10-001){ref-type="table-fn"}   26.2 ± 9.1      25.8 ± 9.7          0.23             5.98    2.11    0.006[\*](#tfn2-ARYA-10-001){ref-type="table-fn"}
  CI          4.2 ± 1.7            4.4 ± 1.8       0.360                                               3.8 ± 1.4       4.0 ± 1.3           0.41             -1.56   1.74    0.370
  NYHA FC     2.7 ± 0.7            2.3 ± 0.7       0.025[\*](#tfn2-ARYA-10-001){ref-type="table-fn"}   2.9 ± 0.8       2.7 ± 0.7           0.17             -0.48   0.15    0.002[\*](#tfn2-ARYA-10-001){ref-type="table-fn"}
  CRP         3.7 ± 2.1            3.5 ± 2.3       0.130                                               4.6 ± 2.7       4.5 ± 3.3           0.22             -0.14   0.40    0.900
  ESR         13.6 ± 13.3          11.6 ± 15.2     0.110                                               6.7 ± 5.1       6.3 ± 4.6           0.31             1.83    5.76    0.750
  LDL         106.7 ± 32.8         93.4 ± 29.3     0.150                                               87.4 ± 15.7     88.1 ± 16.0         0.42             0.02    0.34    0.930
  TC          120.2 ± 39.7         114.2 ± 44.2    0.130                                               146.0 ± 40.1    138.2 ± 40.8        0.35             -0.09   0.69    0.890
  NT-proBNP   561.9 ± 293.7        541.6 ± 469.0   0.510                                               518.1 ± 218.5   484.6 ± 186.6       0.38             13.23   81.80   0.870

Data are presented as mean ± standard deviation; NYHA FC: New York Heart Association Functional Class; EF: Ejection fraction; CI: Cardiac index; CRP: C -reactive protein; ESR: Erythrocyte sedimentation rate; LDL: Low density lipoprotein; TC: Total cholesterol; NT-proBNP: N- terminal B-type Natriuretic Peptide

P \< 0.05 considered significant
